Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) - Pipeline Insight, 2020

February 2020 | 106 pages | ID: RDF8BF967376EN
DelveInsight

Abstracts

This report can be delivered to the clients within 48-72 Hours

Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Overview
'Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Pipeline Insight, 2020' Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Market. A Detailed Picture Of The Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Pipeline Landscape Is Provided, Which Includes The Disease Overview And Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Treatment Guidelines.

The Assessment Part Of The Report Embraces In-Depth Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Commercial Assessment And Clinical Assessment Of The Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.

In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.
Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Of Pipeline Development Activities

The Report Provides Insights Into:

• All Of The Companies That Are Developing Therapies For The Treatment Of Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) With Aggregate Therapies Developed By Each Company For The Same.
• Different Therapeutic Candidates Segmented Into Early-Stage, Mid-Stage And Late Stage Of Development For The Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Treatment.
• Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Key Players Involved In Targeted Therapeutics Development With Respective Active And Inactive (Dormant Or Discontinued) Projects.
• Drugs Under Development Based On The Stage Of Development, Route Of Administration, Target Receptor, Monotherapy Or Combination Therapy, A Different Mechanism Of Action, And Molecular Type.
• Detailed Analysis Of Collaborations (Company-Company Collaborations And Company-Academia Collaborations), Licensing Agreement And Financing Details For Future Advancement Of Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Market.
• The Report Is Built Using Data And Information Traced From The Researcher's Proprietary Databases, Company/University Websites, Clinical Trial Registries, Conferences, SEC Filings, Investor Presentations, And Featured Press Releases From Company/University Web Sites And Industry-Specific Third-Party Sources, Etc.

Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Analytical Perspective By DelveInsight

• In-Depth Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Commercial Assessment Of Products

This Report Provides A Comprehensive Commercial Assessment Of Therapeutic Drugs That Have Been Included, Which Comprises Of Collaborations, Licensing, And Acquisition Deal Value Trends. The Report Also Covers Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, And Acquisition Analysis In Both Graphical And Tabulated Form In A Detailed Manner.

• Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Clinical Assessment Of Products

The Report Comprises Of Comparative Clinical Assessment Of Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type Across This Indication.

SCOPE OF THE REPORT

• The Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Report Provides An Overview Of Therapeutic Pipeline Activity And Therapeutic Assessment Of The Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type For Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.
• It Comprises Of Detailed Profiles Of Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Therapeutic Products With Key Coverage Of Developmental Activities, Including Technology, Collaborations, Licensing, Mergers And Acquisition, Funding, Designations And Other Product-Related Details
• Detailed Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Research And Development Progress And Trial Details, Results Wherever Available, Are Also Included In The Pipeline Study.
• Coverage Of Dormant And Discontinued Pipeline Projects Along With The Reasons If Available Across Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS).

REPORT HIGHLIGHTS

• A Better Understanding of Disease Pathogenesis Contributing To The Development Of Novel Therapeutics For Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS).
• In The Coming Years, The Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Market Is Set To Change Due To The Rising Awareness Of The Disease, And Incremental Healthcare Spending Across The World; Which Would Expand The Size Of The Market To Enable The Drug Manufacturers To Penetrate More Into The Market.
• The Companies And Academics That Are Working To Assess Challenges And Seek Opportunities That Could Influence Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) R&D. The Therapies Under Development Are Focused On Novel Approaches To Treat/Improve The Disease Condition.
• A Detailed Portfolio of Major Pharma Players Who Are Involved In Fueling The Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Treatment Market. Several Potential Therapies For Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Market Size In The Coming Years.
• Our In-Depth Analysis Of The Pipeline Assets (In Early-Stage, Mid-Stage And Late Stage Of Development For The Treatment Of Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) ) Includes Therapeutic Assessment And Comparative Analysis. This Will Support The Clients In The Decision-Making Process Regarding Their Therapeutic Portfolio By Identifying The Overall Scenario Of The Research And Development Activities.

KEY QUESTIONS

• What Are The Current Options For Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Treatment?
• How Many Companies Are Developing Therapies For The Treatment Of Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS)?
• What Are The Principal Therapies Developed By These Companies In The Industry?
• How Many Therapies Are Developed By Each Company For The Treatment Of Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS)?
• How Many Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Emerging Therapies Are In Early-Stage, Mid-Stage, And Late Stage Of Development For The Treatment Of Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS)?
• Out Of Total Pipeline Products, How Many Therapies Are Given As A Monotherapy And In Combination With Other Therapies?
• What Are The Key Collaborations (Industry-Industry, Industry-Academia), Mergers And Acquisitions, And Major Licensing Activities That Will Impact Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Market?
• Which Are The Dormant And Discontinued Products And The Reasons For The Same?
• What Is The Unmet Need For Current Therapies For The Treatment Of Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS)?
• What Are The Recent Novel Therapies, Targets, Mechanisms Of Action And Technologies Developed To Overcome The Limitation Of Existing Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Therapies?
• What Are The Clinical Studies Going On For Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) And Their Status?
• What Are The Results Of The Clinical Studies And Their Safety And Efficacy?
• What Are The Key Designations That Have Been Granted For The Emerging Therapies For Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS)?
• How Many Patents Are Granted And Pending For The Emerging Therapies For The Treatment Of Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS)?

Contents

1. REPORT INTRODUCTION

2. RELAPSED OR REFRACTORY MYCOSIS FUNGOIDES (MF) AND SЙZARY SYNDROME (SS)

2.1. Overview
2.2. History
2.3. Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Diagnosis
  2.6.1. Diagnostic Guidelines

3. RELAPSED OR REFRACTORY MYCOSIS FUNGOIDES (MF) AND SЙZARY SYNDROME (SS) CURRENT TREATMENT PATTERNS

3.1. Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Treatment Guidelines

4. RELAPSED OR REFRACTORY MYCOSIS FUNGOIDES (MF) AND SЙZARY SYNDROME (SS) - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment
  4.1.1. Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) companies collaborations, Licensing, Acquisition -Deal Value Trends
    4.1.1.1. Assessment Summary
  4.1.2. Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Collaboration Deals
    4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
    4.1.2.3. Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Acquisition Analysis

5. THERAPEUTIC ASSESSMENT

5.1. Clinical Assessment of Pipeline Drugs
  5.1.1. Assessment by Phase of Development
  5.1.2. Assessment by Product Type (Mono / Combination)
    5.1.2.1. Assessment by Stage and Product Type
  5.1.3. Assessment by Route of Administration
    5.1.3.1. Assessment by Stage and Route of Administration
  5.1.4. Assessment by Molecule Type
    5.1.4.1. Assessment by Stage and Molecule Type
  5.1.5. Assessment by MOA
    5.1.5.1. Assessment by Stage and MOA
  5.1.6. Assessment by Target
    5.1.6.1. Assessment by Stage and Target

6. RELAPSED OR REFRACTORY MYCOSIS FUNGOIDES (MF) AND SЙZARY SYNDROME (SS) LATE STAGE PRODUCTS (PHASE-III)

7. RELAPSED OR REFRACTORY MYCOSIS FUNGOIDES (MF) AND SЙZARY SYNDROME (SS) MID STAGE PRODUCTS (PHASE-II)

8. EARLY STAGE PRODUCTS (PHASE-I)

9. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS

10. INACTIVE PRODUCTS

11. DORMANT PRODUCTS

12. RELAPSED OR REFRACTORY MYCOSIS FUNGOIDES (MF) AND SЙZARY SYNDROME (SS) DISCONTINUED PRODUCTS

13. RELAPSED OR REFRACTORY MYCOSIS FUNGOIDES (MF) AND SЙZARY SYNDROME (SS) PRODUCT PROFILES

13.1. Drug Name: Company
  13.1.1. Product Description
    13.1.1.1. Product Overview
    13.1.1.2. Mechanism of action
  13.1.2. Research and Development
    13.1.2.1. Clinical Studies
  13.1.3. Product Development Activities
    13.1.3.1. Collaboration
    13.1.3.2. Agreements
    13.1.3.3. Acquisition
    13.1.3.4. Patent Detail
  13.1.4. Tabulated Product Summary
    13.1.4.1. General Description Table
Detailed information in the report?

14. RELAPSED OR REFRACTORY MYCOSIS FUNGOIDES (MF) AND SЙZARY SYNDROME (SS) KEY COMPANIES

15. RELAPSED OR REFRACTORY MYCOSIS FUNGOIDES (MF) AND SЙZARY SYNDROME (SS) KEY PRODUCTS

16. DORMANT AND DISCONTINUED PRODUCTS

16.1. Dormant Products
  16.1.1. Reasons for being dormant
16.2. Discontinued Products
  16.2.1. Reasons for the discontinuation

17. RELAPSED OR REFRACTORY MYCOSIS FUNGOIDES (MF) AND SЙZARY SYNDROME (SS) UNMET NEEDS

18. RELAPSED OR REFRACTORY MYCOSIS FUNGOIDES (MF) AND SЙZARY SYNDROME (SS) FUTURE PERSPECTIVES

19. RELAPSED OR REFRACTORY MYCOSIS FUNGOIDES (MF) AND SЙZARY SYNDROME (SS) ANALYST REVIEW

20. APPENDIX

21. REPORT METHODOLOGY

21.1. Secondary Research
21.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

Table 1: Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Diagnostic Guidelines
Table 2: Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Late Stage Products (Phase-III)
Table 18: Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Mid Stage Products (Phase-II)
Table 19: Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products

List Of Figures

LIST OF FIGURES

Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: Relapsed or Refractory Mycosis Fungoides (MF) AND Sйzary Syndrome (SS) Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs